index

MERCK MAKING NEWS

Latest News

May 27, 2019
Merck Canada Welcomes the Government of British Columbia’s Biosimilars Initiative

May 8, 2019
FIRST AND ONLY PARP INHIBITOR, LYNPARZA^® (OLAPARIB) APPROVED AS A FIRST-LINE MAINTENANCE THERAPY TREATMENT IN BRCA-MUTATED ADVANCED OVARIAN CANCER

March 18, 2019
New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

November 19, 2018
Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in life sciences

September 11, 2018
Important Information on MARVELON^® 28 (Desogestrel/Ethinyl Estradiol) Oral Contraceptive Tablets – Absence of Day-of-the-Week Label Stickers

June 20, 2017
Major Funding Expected in Support of Alberta’s Life Sciences’ Sector

May 25, 2017
Indigenous Researchers Receive $2.6 Million Funding From Merck Canada Inc. for Indigenous Maternal and Child Health Program in Ontario

May 8, 2017
Recent Floods: Alert for Merck Canada Inc. Employees

April 21, 2017
Merck Applauds World Health Organization’s (WHO) World Immunization Week

This website is designed to provide members of the media with quick and easy access to recent information about Merck. For additional information, please visit 'About Merck'.

MEDIA CENTRE

For journalists with a media inquiry, please contact us: 1-833-90MERCK (1-833-906-3725).

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.